Abbott Laboratories logo

Abbott Laboratories (ABT)

Market Open
25 Feb, 15:14
NYSE NYSE
$
115. 26
+0.68
+0.59%
$
195.3B Market Cap
36.49 P/E Ratio
0.79% Div Yield
943,396 Volume
4.44 Eps
$ 114.58
Previous Close
Day Range
114.69 116.02
Year Range
105.27 141.23
Want to track ABT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
ABT earnings report is expected in 48 days (14 Apr 2026)
Abbott Laboratories Employees Credit Union (“ALECU”) Data Breach under Investigation by Levi & Korsinsky

Abbott Laboratories Employees Credit Union (“ALECU”) Data Breach under Investigation by Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / October 28, 2024 / Abbott Laboratories Employees Credit Union ("ALECU") recently disclosed a data breach that compromised the sensitive personal data of thousands of customers. This data breach has led to concerns over the security of sensitive private information entrusted to ALECU.

Accesswire | 1 year ago
Growing Biosimilars Business Supports ABT Stock, Macro Issues Hurt

Growing Biosimilars Business Supports ABT Stock, Macro Issues Hurt

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.

Zacks | 1 year ago
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It

Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It

Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks | 1 year ago
Abbott Laboratories: Promising Growth, Yet Fully Valued; A Wait-And-Watch Stock

Abbott Laboratories: Promising Growth, Yet Fully Valued; A Wait-And-Watch Stock

Abbott Laboratories, a healthcare giant with diverse divisions, is normalizing post-pandemic as its medical devices drive growth following a drop in Covid-test demand. The company reported 9% revenue growth in terms of pure organic sales, with several of its segments reeling in double-digit growth. ABT appears fairly valued, showing no strong buy or sell signals based on its P/E to EPS growth relationship.

Seekingalpha | 1 year ago
What Drove Abbott's Q3?

What Drove Abbott's Q3?

Abbott (NYSE: ABT) recently reported its Q3 results, with revenues and earnings slightly above our expectations. The company reported revenue of $10.64 billion and earnings of $1.21 on a per-share and adjusted basis, compared to our estimates of $10.55 billion and $1.20, respectively.

Forbes | 1 year ago
Abbott Laboratories: Long-Term Optimism, Short-Term Overvaluation

Abbott Laboratories: Long-Term Optimism, Short-Term Overvaluation

Abbott Laboratories is a diversified healthcare company with strong segments, particularly Medical Devices, contributing to steady growth and consistent dividends. ABT's Q2 earnings showed solid performance, with Medical Devices leading organic revenue growth, despite some segments facing challenges including discontinuing products and COVID-19 sales decline. The company authorized a new $7 billion buyback program, reinforcing its commitment to returning cash to shareholders through dividends and share repurchases.

Seekingalpha | 1 year ago
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever

Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever

These companies' longtime shareholders have generally been rewarded.

Fool | 1 year ago
3 Fortune 500 Industry Leaders Boast Ideal October Dividends

3 Fortune 500 Industry Leaders Boast Ideal October Dividends

The June/July 2024 edition of Fortune revealed the 500 biggest U.S. companies by revenue and profits. Dogcatcher's quest to sniff-out the best dividend-buys focused on 66 industry-leader profits per YCharts data 10/16/24. Those 66 industry leaders were segmented into 21 business sectors, ranging (alphabetically) from apparel to wholesalers. 3 of the 66 were private or foreign exchange listed firms, not tracked by YCharts, leaving 63-listed. 57 dividend-yielding stocks led those 63 industry leaders and ranged 0.03% to 8.13% in annual yield and ranged -12.12% to 55.72% in broker-estimated one-year target-price-upsides.

Seekingalpha | 1 year ago
Wall Street Analysts Think Abbott (ABT) Is a Good Investment: Is It?

Wall Street Analysts Think Abbott (ABT) Is a Good Investment: Is It?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Zacks | 1 year ago
3 No-Brainer Pharmaceutical Stocks to Buy With $500 Right Now

3 No-Brainer Pharmaceutical Stocks to Buy With $500 Right Now

These stocks could deliver big over the long term.

Fool | 1 year ago
Abbott Labs Path to Double-Digit Earnings Growth In 2025? This Analyst Is Optimistic

Abbott Labs Path to Double-Digit Earnings Growth In 2025? This Analyst Is Optimistic

On Wednesday, Abbott Laboratories ABT reported third-quarter sales of $10.64 billion, up 4.9% year over year, beating the consensus of $10.55 billion.

Benzinga | 1 year ago
Abbott's Growth and Dividends Make It a Smart Portfolio Pick

Abbott's Growth and Dividends Make It a Smart Portfolio Pick

There are many reasons to own Abbott Laboratories ABT, but they all boil down to one thing: consistent market-beating returns. A study published by Hendrik Bessembinder, a professor of finance at Arizona State University, found that Abbott is the 11th top-returning stock since 1937 and #1 among healthcare names.

Benzinga | 1 year ago
Loading...
Load More